Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Opthea Ltd ADR (OPT)

Opthea Ltd ADR (OPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 200,295
  • Shares Outstanding, K 58,395
  • Annual Sales, $ 110 K
  • Annual Income, $ -142,520 K
  • 60-Month Beta 1.19
  • Price/Sales 1,816.73
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade OPT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.20 +13.44%
on 04/19/24
4.40 -17.50%
on 04/01/24
-0.07 (-1.89%)
since 03/25/24
3-Month
2.50 +45.20%
on 01/30/24
4.40 -17.50%
on 04/01/24
+1.00 (+38.02%)
since 01/25/24
52-Week
1.60 +126.88%
on 10/27/23
4.42 -17.87%
on 05/01/23
+0.11 (+3.13%)
since 04/25/23

Most Recent Stories

More News
Opthea To Present at Upcoming Investor Conferences

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea Presentation at The Retina World Congress 2022

MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea strengthens its Board of Directors

Elects Mr. Quinton Oswald and Dr. ...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer

Key appointment as Opthea progresses the Phase 3 clinical development of OPT-302 in wet AMD MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) --...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea To Present at SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)
Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.632 (-6.37%)
OPT : 3.63 (+5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Opthea Limited is a biotechnology company. It develops and commercializes therapies primarily for eye disease principally in Australia. Opthea Limited is based in South Yarra, Australia.

See More

Key Turning Points

3rd Resistance Point 3.94
2nd Resistance Point 3.79
1st Resistance Point 3.71
Last Price 3.63
1st Support Level 3.49
2nd Support Level 3.35
3rd Support Level 3.26

See More

52-Week High 4.42
Last Price 3.63
Fibonacci 61.8% 3.34
Fibonacci 50% 3.01
Fibonacci 38.2% 2.68
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar